Search Results

Another Option Available for Multiple Myeloma Patients

Just on the heels of two approvals last week, the FDA today approved a third therapy to treat patients with multiple myeloma. Elotuzumab (Emplicity ™) is approved for use in combination with another drug, lenalidomide (Revlimid ®) for patients who have failed previous therapies.

A Multiple Myeloma Patient Rebuilds His Life

I have always been a builder.

​Professionally, I am an architect. I have designed housing, theaters, libraries, a police station house, social service facilities, cultural centers and museums. 

​I am also a builder of communities, working with local organizations to help alleviate poverty, violence, and social disenfranchisement. 

FDA Approves Novel Car T-Immunotherapy for the Treatment of Multiple Myeloma

New Drug Approval Moves Us Closer To Long-Term Control of Multiple Myeloma

An Emerging Target for Myeloma Therapy Could Prove a Game-Changer

Multiple Myeloma 3D Model

.model-icon-key-mobile{ display:none;} @media only screen and (max-width: 767px) { .model-icon-key-desktop{ display: none;} .model-icon-key-mobile{ display: block;} }

This model contains the following chapters. Click the "Interact in 3D" button to begin.

• Healthy Bone Marrow
• Normal Blood Cell Production
• Proliferation of Cells and the Crowding Out of Normal Cells
• Osteoclasts and Osteoblasts in Multiple Myeloma

Understanding Myeloma: A Quick Guide

Myeloma is a rare blood cancer

 

Ask the Doctor Part 3: Five Questions about Myeloma

Myeloma Survivor, Sharon Clark Talks to Dr. Nichols about the Latest in Myeloma Research and Treatment

My Myeloma Story

“What is multiple myeloma?” Those were my words after the doctor’s review of my lab results for a routine and random high blood pressure exam in November 2008.

How to Deal with Goliath: Your Myeloma Diagnosis

Guest blogger Yelak talks about leading and directing your medical team

Who is Goliath? Goliath, in the Bible, was a giant who couldn’t be defeated because of his huge size and power. In our world of myeloma today, Goliath is the might of medical care, medical insurance, treatment options, clinical trials and all the daunting tasks of living and dealing with myeloma.

I Lost My Husband to Myeloma, A Blood Cancer

Meet Three Women in Science Championing Myeloma Cures and Care

Living with Multiple Myeloma

Advances in Multiple Myeloma

Spotlight On Multiple Myeloma

Enhancing CAR T cell therapy for multiple myeloma

My overall focus is to improve CAR T cell therapy for multiple myeloma. Our clinical trial uses CAR T cells targeting BCMA as first line therapy for high-risk multiple myeloma to assess whether early use of CAR T cells is safer and more effective than use in patients with relapsed disease. Half of patients will also receive CAR T cells targeting CD19 to assess whether this can improve the duration of response to anti-BCMA CAR T cells. Our goal is to evaluate whether early use of CAR T cells is a safer and more effective way to use CAR T cells for multiple myeloma patients.

Improving outcomes with immune therapies for multiple myeloma

The primary focus of research is to better understand mechanisms of resistance to immunotherapies and design treatment approaches to improve outcomes. I hope to accomplish this by conducting clinical trials that concurrently target both BCMA and GPRC5D in patients with advanced multiple myeloma and by studying antigen expression, tumor genetics, and T cell characteristics to better understand mechanisms of resistance. The goal is to develop more effective immune treatments for myeloma.

More Progress in Cancer Research at #ASCO18

Chicago is once again the site of the annual American Society of Clinical Oncology Meeting (#ASCO18), where more than 30,000 scientists, advocates and representatives from the biopharmaceutical industry have gathered to share the their latest clinical findings and to learn from each other in education sessions, scientific presentations and opportunities for networking. The meeting began Friday and continues through Tuesday.

Investigating the Role of Adenylate Kinase 2 in Multiple Myeloma

The goal of my research is to characterize the role of the cellular metabolic regulator AK2 in multiple myeloma (MM) pathogenesis and therapy resistance. A series of molecular, biochemical, and functional assays will be performed using laboratory models to define the basis of MM cell dependence on AK2 and elucidate its role in MM progression and drug resistance. This work will highlight novel metabolic vulnerabilities in MM that can be targeted to further enhance therapeutic outcomes.

More Updates from #ASCO19: Access, Priorities and Progress

Limited-duration bispecific antibody therapy for multiple myeloma

Bispecific antibodies are a new, highly effective immunotherapy for multiple myeloma. Most bispecific antibody therapies have been tested as continuous therapies in which patients continue receiving the treatment until the myeloma starts growing again. Preliminary results suggest that patients with good responses may be able to stop therapy and enjoy a period of time off-therapy with close observation, which may limit long term toxicities caused by continuous therapy.

Treatment Updates: Multiple Myeloma

Optimizing Outcomes: Multiple Myeloma

Emerging Therapies for Multiple Myeloma